Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of May 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing primarily serves to incorporate by reference a press release dated May 30, 2018 (Exhibit 99.1), which is attached to the report.
Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts as a conduit for the attached press release rather than a financial statement.
Material Changes
The filing text does not detail specific material changes in financial position or operations compared to prior periods. It references the incorporation of a press release into registration statements but does not summarize the content of that release within the body of the Form 6-K.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, or specific risk factors. It notes that the information in the report, including exhibits, is incorporated by reference into various Registration Statements (Forms F-3 and S-8). Specific quotes from Dr. Philip Mease, Dr. Walid Abi-Saab, and Dr. John McHutchison are mentioned as being contained in Exhibit 99.1 but are not reproduced in the filing text.
Key Facts for Investor Verification
- Verify the actual content of the May 30, 2018 press release (Exhibit 99.1), as the Form 6-K text only references it without summarizing its substance.
- Confirm the registrant is Galapagos NV, noting a discrepancy with the metadata company name "Lakefront Biotherapeutics NV."
- Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, etc.) for the full context of the incorporated information.
- Note that this filing was signed on June 5, 2018, by Xavier Maes, Company Secretary.